Evaluation of the Effectiveness of Immunosorbent-Based Hemosorption in Comprehensive Conservative Therapy of End-Stage Heart Failure Patients

Keywords: dilated cardiomyopathy, immunosorbent, left ventricular ejection fraction, brain natriuretic peptide

Abstract

Background. Heart failure is the leading cause of death among all cardiovascular diseases. The five-year survival rate in such patients is 50%. In most cases, heart transplantation is the treatment of choice in these patients. However, its use is limited by severe and progressive donor organ deficiency.

The aim. To study the effectiveness of immunosorbent-based hemosorption in comprehensive conservative treatment of patients with end-stage heart failure.

Materials and methods. A retrospective analysis of the results of treatment in 59 patients 90% men, 10% women; mean age 41.3 ± 12.4 years; NYHA IIB-III, baseline left ventricular ejection fraction 21.1 ± 4.66%, left ventricular endsystolic volume 206.87 ± 84.1 ml, left ventricular end-diastolic volume 264.4 ± 86.02 ml) hospitalized for end-stage heart failure was performed. Conservative therapy was carried out following international guidelines and was supplemented by a course of 2-4 hemosorption procedures for which hemosorbent granulated deliganding was used. The Student’s t-test was used to analyze the data.

Results. The clinical condition of all patients improved after the performed hemosorption procedures by at least one NYHA class. The brain natriuretic peptide level decreased from 1281.17±165.33 pg/ml to 859.48±113.38 pg/ml (p<0.05). Left ventricular ejection fraction increased by 10.77±4.3% (to 29.36 ± 6.27%) (p<0.01), and after 12 months it was 34 ± 2.59% (p<0.05). Left ventricular end-systolic volume decreased by 68.75±43.56 ml (to 137.77 ± 33.21 ml), left ventricular end-diastolic volume decreased by 41.38±31.48 ml (to 238.04 ± 82.1 ml) (p<0.05).

Conclusions. The use of hemosorption with hemosorbent granulated deliganding, against the background of conservative treatment of end-stage heart failure, improves the contractile function of the heart and general clinical condition of patients.

References

  1. Kaipbergenova ShN, Rakhimov RR, editors. [Epidemiology of chronic cardiac insufficiency]. The modern progress of education, science and technologies trends: Proceedings of the VII International scientific practical conference; 2018. Russian.
  2. Nasonova SN, Zhyrov IV, Tereschenko SN. [What do we know about sharp cardiac insufficiency?]. Neotlozhnaya kardiologiya. 2015;(1): 3-11. Russian.
  3. Zarudskiy AA, Shelyakina EV, Shkileva IYu. [Epidemiology of chronic systole cardiac insufficiency on the modern stage]. Zdorov′ye i obrazovaniye XXI veka. 2017;(12):167-71. Russian.
  4. Nguyen VQ, Celebi MM, Suleman A. Dilated Cardiomyopathy [Internet]. Medscape; 2021 Mar 02 [cited 2022 Jan 27]. Available from: https://emedicine.medscape.com/article/152696-overview/
  5. Okamoto C, Tsukamoto O, Hasegawa T, Hitsumoto T, Matsuoka K, Takashima S, Amaki M, Kanzaki H, Izumi C, Ito S, Kitakaze M. Lower B-type natriuretic peptide levels predict left ventricular concentric remodelling and insulin resistance. ESC Heart Fail. 2022;9(1):636-47. https://doi.org/10.1002/ehf2.13700
  6. Kovtun HI. Khirurhichne remodeliuvannia livoho shlunochka pry terminalnii stadii sertsevoi nedostatnosti u khvorykh shcho znakhodiatsia na lysti ochikuvannia transplantatsii sertsia [Surgical remodeling of the left ventricle in end-stage heart failure in patients on the waiting list for heart transplantation [dissertation]. Kyiv; 2012. Ukrainian.
  7. Kulikova VA, Nedostup AV, Blagova OV, Zaydenov VA, Kupriyanova AG, Nechaev IA, Ragimov AA. [Therapeutic plasma exchange in patients with inflammatory dilated cardiomyopathy]. Clin Experiment Surg. Petrovsky J. 2019;7(1): 6-16. Russian. https://doi.org/10.24411/2308-1198-2019-11001
  8. Mazurenko O, Nadzyakevych P, Loskutov O, Zgrzheblovskaya L. [Analysis of non-surgical complications in patients with implanted left ventricular assist devices]. Emergency medicine. 2019;99(4):88-94. Ukrainian. https://doi.org/10.22141/2224-0586.4.99.2019.173939
  9. Ameling S, Bhardwaj G, Hammer E, Beug D, Steil L, Reinke Y, Weitmann K, Grube M, Trimpert C, Klingel K, Kandolf R, Hoffmann W, Nauck M, Dörr M, Empen K, Felix SB, Völker U. Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution. Basic Res Cardiol. 2016;111(5):53. https://doi.org/10.1007/s00395-016-0569-y
  10. Yoshikawa T, Baba A, Akaishi M, Wakabayashi Y, Monkawa T, Kitakaze M, Izumi T, Tomoike H. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column – A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. J Clin Apher. 2016;31(6):535-44. https://doi.org/10.1002/jca.21446
  11. Ohlow MA, Brunelli M, Schreiber M, Lauer B. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry. J Cardiol. 2017;69(2):409-16. https://doi.org/10.1016/j.jjcc.2016.07.014
Published
2022-03-23
How to Cite
Denysiuk, K. V., Loskutov, O. A., & Druzhyna, O. M. (2022). Evaluation of the Effectiveness of Immunosorbent-Based Hemosorption in Comprehensive Conservative Therapy of End-Stage Heart Failure Patients. Ukrainian Journal of Cardiovascular Surgery, 30(1), 43-48. https://doi.org/10.30702/ujcvs/22.30(01)/DL012-4348
Section
PATHOLOGY of MYOCARD and HEART FAILURE